Pharmacotherapy and Intensive Treatment - 2
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders; Substance-Related Disorders
Intervention: Carbamazepine (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
William Haning, M.D., Principal Investigator, Affiliation: University of Kansas
Summary
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine
craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric
disorders.
Clinical Details
Official title: Pharmacotherapy and Intensive Treatment
Study design: Treatment
Primary outcome: Severity addictionDepression Depression, anxiety
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Female.
Criteria:
Please contact site for information.
Locations and Contacts
University of Kansas, Kansas City, Missouri 64128, United States
Additional Information
Last updated: June 23, 2005
|
